NUVL
Price
$81.39
Change
+$3.87 (+4.99%)
Updated
Sep 26 closing price
Capitalization
5.87B
40 days until earnings call
RARE
Price
$29.08
Change
+$1.26 (+4.53%)
Updated
Sep 26 closing price
Capitalization
2.8B
38 days until earnings call
Interact to see
Advertisement

NUVL vs RARE

Header iconNUVL vs RARE Comparison
Open Charts NUVL vs RAREBanner chart's image
Nuvalent
Price$81.39
Change+$3.87 (+4.99%)
Volume$371.19K
Capitalization5.87B
Ultragenyx Pharmaceutical
Price$29.08
Change+$1.26 (+4.53%)
Volume$2.66M
Capitalization2.8B
NUVL vs RARE Comparison Chart in %
Loading...
NUVL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NUVL vs. RARE commentary
Sep 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NUVL is a Buy and RARE is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 27, 2025
Stock price -- (NUVL: $81.39 vs. RARE: $29.08)
Brand notoriety: NUVL and RARE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NUVL: 83% vs. RARE: 156%
Market capitalization -- NUVL: $5.87B vs. RARE: $2.8B
NUVL [@Biotechnology] is valued at $5.87B. RARE’s [@Biotechnology] market capitalization is $2.8B. The market cap for tickers in the [@Biotechnology] industry ranges from $98.9B to $0. The average market capitalization across the [@Biotechnology] industry is $1.9B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NUVL’s FA Score shows that 0 FA rating(s) are green whileRARE’s FA Score has 0 green FA rating(s).

  • NUVL’s FA Score: 0 green, 5 red.
  • RARE’s FA Score: 0 green, 5 red.
According to our system of comparison, NUVL is a better buy in the long-term than RARE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NUVL’s TA Score shows that 7 TA indicator(s) are bullish while RARE’s TA Score has 5 bullish TA indicator(s).

  • NUVL’s TA Score: 7 bullish, 3 bearish.
  • RARE’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, NUVL is a better buy in the short-term than RARE.

Price Growth

NUVL (@Biotechnology) experienced а +6.16% price change this week, while RARE (@Biotechnology) price change was +3.38% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.00%. For the same industry, the average monthly price growth was +9.18%, and the average quarterly price growth was +54.60%.

Reported Earning Dates

NUVL is expected to report earnings on Nov 06, 2025.

RARE is expected to report earnings on Nov 04, 2025.

Industries' Descriptions

@Biotechnology (+4.00% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NUVL($5.87B) has a higher market cap than RARE($2.8B). NUVL YTD gains are higher at: 3.973 vs. RARE (-30.877). NUVL has higher annual earnings (EBITDA): -362.01M vs. RARE (-435.33M). NUVL has more cash in the bank: 1.01B vs. RARE (477M). RARE has higher revenues than NUVL: RARE (610M) vs NUVL (0).
NUVLRARENUVL / RARE
Capitalization5.87B2.8B209%
EBITDA-362.01M-435.33M83%
Gain YTD3.973-30.877-13%
P/E RatioN/AN/A-
Revenue0610M-
Total Cash1.01B477M211%
Total DebtN/A36.3M-
FUNDAMENTALS RATINGS
RARE: Fundamental Ratings
RARE
OUTLOOK RATING
1..100
57
VALUATION
overvalued / fair valued / undervalued
1..100
71
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
87
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
NUVLRARE
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
87%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
82%
MACD
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
76%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend about 1 month ago
78%
Declines
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 12 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
76%
Bullish Trend 2 days ago
77%
Aroon
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
69%
View a ticker or compare two or three
Interact to see
Advertisement
NUVL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ISPVX20.450.19
+0.94%
Macquarie Smid Cap Core Fund R6
GGOCX22.240.20
+0.91%
Goldman Sachs Mid Cap Growth C
CLPYX58.170.34
+0.59%
Columbia Large Cap Index Inst3
JDBAX50.780.12
+0.24%
Janus Henderson Balanced A
IAFLX21.94-0.02
-0.09%
F/m Investments Large Cap Focused Inst

NUVL and

Correlation & Price change

A.I.dvisor indicates that over the last year, NUVL has been loosely correlated with XENE. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if NUVL jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NUVL
1D Price
Change %
NUVL100%
+4.99%
XENE - NUVL
60%
Loosely correlated
+4.00%
CGON - NUVL
58%
Loosely correlated
+2.91%
CRNX - NUVL
57%
Loosely correlated
+27.92%
RVMD - NUVL
57%
Loosely correlated
+3.32%
IDYA - NUVL
57%
Loosely correlated
+4.44%
More

RARE and

Correlation & Price change

A.I.dvisor indicates that over the last year, RARE has been closely correlated with MREO. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if RARE jumps, then MREO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RARE
1D Price
Change %
RARE100%
+4.53%
MREO - RARE
71%
Closely correlated
+9.60%
CRNX - RARE
50%
Loosely correlated
+27.92%
NRIX - RARE
49%
Loosely correlated
+7.20%
IONS - RARE
47%
Loosely correlated
+1.78%
NUVL - RARE
46%
Loosely correlated
+4.99%
More